These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26758563)

  • 21. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
    Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
    J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors.
    Eickhoff MK; Dekkers CCJ; Kramers BJ; Laverman GD; Frimodt-Møller M; Jørgensen NR; Faber J; Danser AHJ; Gansevoort RT; Rossing P; Persson F; Heerspink HJL
    J Clin Med; 2019 May; 8(6):. PubMed ID: 31159350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED).
    Zainordin NA; Hatta SFWM; Mohamed Shah FZ; Rahman TA; Ismail N; Ismail Z; Abdul Ghani R
    J Endocr Soc; 2020 Jan; 4(1):bvz017. PubMed ID: 31993550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Dapagliflozin Treatment on Serum Sodium Concentrations in Acute Heart Failure.
    Charaya K; Shchekochikhin D; Agadzhanyan A; Vashkevich M; Chashkina M; Kulikov V; Andreev D
    Cardiorenal Med; 2023; 13(1):101-108. PubMed ID: 36806178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of co-trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial.
    Chan WY; Clark AB; Wilson AM; Loke YK;
    Br J Clin Pharmacol; 2017 Aug; 83(8):1808-1814. PubMed ID: 28192629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline.
    Stefánsson BV; Heerspink HJL; Wheeler DC; Sjöström CD; Greasley PJ; Sartipy P; Cain V; Correa-Rotter R
    Data Brief; 2021 Aug; 37():107237. PubMed ID: 34258337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial.
    Hao Z; Huang X; Shao H; Tian F
    Ther Clin Risk Manag; 2018; 14():2407-2413. PubMed ID: 30587997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.
    Gilbert RE; Mende C; Vijapurkar U; Sha S; Davies MJ; Desai M
    Diabetes Ther; 2017 Apr; 8(2):451-458. PubMed ID: 28197834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin.
    Zhao YX; Borjigin S; Yan ZL
    World J Diabetes; 2022 Mar; 13(3):224-239. PubMed ID: 35432754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevalence of hyperkalemia and its effects on mortality in hospitalized patients: a single center 10-year retrospective analysis].
    Lai XX; Xu C; Li GS; Wang L
    Zhonghua Yi Xue Za Zhi; 2021 Nov; 101(42):3472-3477. PubMed ID: 34775704
    [No Abstract]   [Full Text] [Related]  

  • 33. Short-term prognosis of normalising serum potassium following an episode of hypokalaemia in patients with chronic heart failure.
    Aldahl M; Polcwiartek C; Davidsen L; Kragholm K; Søgaard P; Torp-Pedersen C; Krogager ML
    Eur J Prev Cardiol; 2021 Apr; 28(3):316-323. PubMed ID: 33891686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.
    Reilly TP; Graziano MJ; Janovitz EB; Dorr TE; Fairchild C; Lee F; Chen J; Wong T; Whaley JM; Tirmenstein M
    Diabetes Ther; 2014 Jun; 5(1):73-96. PubMed ID: 24474422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of propofol and thiopental continuous infusion on serum potassium disturbances in neurosurgical patients.
    Kim TK; Lim YJ; Ju JW; Kim JW; Park HP
    J Korean Neurosurg Soc; 2015 Mar; 57(3):197-203. PubMed ID: 25810860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials.
    Amin AN; Menoyo J; Singh B; Kim CS
    BMC Nephrol; 2019 Dec; 20(1):440. PubMed ID: 31791288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment.
    van der Walt JS; Hong Y; Zhang L; Pfister M; Boulton DW; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2013 May; 2(5):e42. PubMed ID: 23887724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Course of Hyperkalemia in Patients on Hemodialysis.
    Spinowitz B; Fishbane S; Fukagawa M; Ford M; Guzman N; Rastogi A
    Int J Nephrol; 2022; 2022():6304571. PubMed ID: 35531468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Potassium-Sparing Diuretics in the Management of Hypokalemia in Peritoneal Dialysis.
    Nguyen T; Ren S; Hussain J; Balaoro JJ
    Am J Ther; 2021 May-Jun 01; 28(3):e349-e354. PubMed ID: 31567176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium and potassium changes during decongestion with acetazolamide - A pre-specified analysis from the ADVOR trial.
    Dhont S; Martens P; Meekers E; Dauw J; Verbrugge FH; Nijst P; Ter Maaten JM; Damman K; Mebazaa A; Filippatos G; Ruschitzka F; Tang WHW; Dupont M; Mullens W
    Eur J Heart Fail; 2023 Aug; 25(8):1310-1319. PubMed ID: 37062871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.